AbbVie Inc.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $32.75B | $28.22B | $25.64B | $22.86B | $19.96B | $18.79B | $18.38B | $17.44B |
| Humira | $19.94B | $18.43B | $16.08B | — | — | — | — | — |
| Skyrizi | $0 | $0 | — | — | — | — | — | — |
| Rinvoq | $0 | $0 | — | — | — | — | — | — |
| Imbruvica | $3.59B | $2.57B | $1.83B | — | — | — | — | — |
| Venclexta | $344.0M | $122.0M | — | — | — | — | — | — |
| Botox Cosmetic | — | — | — | — | — | — | — | — |
| Botox Therapeutic | — | — | — | — | — | — | — | — |
| Juvederm Collection | — | — | — | — | — | — | — | — |
| Other Aesthetics | — | — | — | — | — | — | — | — |
| Vraylar | — | — | — | — | — | — | — | — |
| Ubrelvy | — | — | — | — | — | — | — | — |
| Qulipta | — | — | — | — | — | — | — | — |
| Vyalev | — | — | — | — | — | — | — | — |
| Other Neuroscience | — | — | — | — | — | — | — | — |
| Elahere | — | — | — | — | — | — | — | — |
| Epkinly | — | — | — | — | — | — | — | — |
| Other Oncology | — | — | — | — | — | — | — | — |
| Ozurdex | — | — | — | — | — | — | — | — |
| Lumigan/Ganfort | — | — | — | — | — | — | — | — |
| Alphagan/Combigan | — | — | — | — | — | — | — | — |
| Restasis | — | — | — | — | — | — | — | — |
| Other Eye Care | — | — | — | — | — | — | — | — |
| Mavyret | $3.44B | $490.0M | — | — | — | — | — | — |
| Creon | $928.0M | $831.0M | $730.0M | — | — | — | — | — |
| Linzess/Constella | — | — | — | — | — | — | — | — |
| Viekira | $178.0M | $784.0M | $1.52B | — | — | — | — | — |
| Orilissa | $11.0M | $0 | — | — | — | — | — | — |
| Lupron | $892.0M | $829.0M | $821.0M | — | — | — | — | — |
| Synagis | $726.0M | $738.0M | $730.0M | — | — | — | — | — |
| Synthroid | $776.0M | $781.0M | $763.0M | — | — | — | — | — |
| Kaletra | $336.0M | $423.0M | $549.0M | — | — | — | — | — |
| Sevoflurane | $391.0M | $410.0M | $428.0M | — | — | — | — | — |
| AndroGel | $469.0M | $577.0M | $675.0M | — | — | — | — | — |
| Duodopa | $430.0M | $355.0M | $293.0M | — | — | — | — | — |
| All other | $308.0M | $876.0M | $1.22B | — | — | — | — | — |
| Cost of Revenue | $7.72B | $7.04B | $5.83B | $4.50B | $4.43B | $4.58B | $4.51B | $4.64B |
| Gross Profit | $25.04B | $21.17B | $19.81B | $18.36B | $15.53B | $14.21B | $13.87B | $12.81B |
| Gross Margin | 76.4% | 75.0% | 77.3% | 80.3% | 77.8% | 75.6% | 75.5% | 73.4% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $7.40B | $6.30B | $5.88B | $6.39B | $7.72B | $5.35B | $4.99B | $5.89B |
| Operating Income | $6.38B | $9.55B | $9.34B | $7.54B | $3.41B | $5.66B | $5.82B | $3.62B |
| Operating Margin | 19.5% | 33.8% | 36.4% | 33.0% | 17.1% | 30.1% | 31.6% | 20.8% |
| Interest Expense | $1.35B | $1.15B | $1.05B | $719.0M | $429.0M | $299.0M | $104.0M | — |
| Pretax Income | $5.20B | $7.73B | $7.88B | $6.65B | $2.37B | $5.33B | $5.73B | $3.67B |
| Income Tax Expense | $-490.0M | $2.42B | $1.93B | $1.50B | $595.0M | $1.20B | $450.0M | $235.0M |
| Net Income | $5.69B | $5.31B | $5.95B | $5.14B | $1.77B | $4.13B | $5.28B | $3.43B |
| Net Margin | 17.4% | 18.8% | 23.2% | 22.5% | 8.9% | 22.0% | 28.7% | 19.7% |
| EPS (Basic) | $3.67 | $3.31 | $3.65 | $3.15 | $1.11 | $2.58 | $3.35 | $2.18 |
| EPS (Diluted) | $3.66 | $3.30 | $3.63 | $3.13 | $1.10 | $2.56 | $3.35 | $2.18 |
| Shares Outstanding (Basic) | 1.54B | 1.60B | 1.62B | 1.63B | 1.60B | 1.59B | 1.58B | 1.58B |
| Shares Outstanding (Diluted) | 1.55B | 1.60B | 1.63B | 1.64B | 1.61B | 1.60B | 1.58B | 1.58B |
| Dividends Per Share | $3.95 | $2.63 | $2.35 | $2.10 | $1.75 | $2.00 | — | — |